SAGE Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare CNS disorders. SAGE's lead program, SAGE-547, is in clinical development for super-refractory status epilepticus and is the first of several compounds the company is developing in its portfolio of potential seizure medicines. SAGE's proprietary chemistry platform has generated multiple new compounds that target GABA A and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders.
SAGE Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare CNS disorders. SAGE's lead program, SAGE-547, is in clinical development for super-refractory status epilepticus and is the first of several compounds the company is developing in its portfolio of potential seizure medicines. SAGE's proprietary chemistry platform has generated multiple new compounds that target GABA A and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders.
Recent Articles
- Skanska Wins Contract for New Health Sciences Center Construction
- AB KN Energies Shares Insights on Financial Results for 2025
- Collaboration Between HD Hyundai and TerraPower Fuels Innovation
- Bekaert's Recent Share Buyback Program and Liquidity Update
- Progress and Insights: ABN AMRO Share Buyback Overview
- Nuclear Supply Chain Partnership between HD Hyundai and TerraPower
- ModivCare Inc. Navigates Bankruptcy with Strategic Financing Boost
- Understanding Aker Carbon Capture ASA's Financial Transition
- Honkarakenne Reports Strong Financial Performance in H1 2025
- Hofseth BioCare ASA Reports Q2 2025 Financial Performance
- ABN AMRO Shares Buyback Update: Recent Progress
- Honkarakenne Oyj Reports Growth in Net Sales Despite Challenges
- ICG Enterprise Trust Executes Share Buyback Transaction
- Huhtamäki Oyj Launches Innovative Euro Medium Term Note Programme
- NB Private Equity Partners Engages in Share Buyback Effort
- Middlefield Canadian Income PCC Moves Forward with ETF Plans
- Hofseth Biocare ASA's Financial Trends and Product Innovations
- Foresight Group Holdings' Ongoing Commitment to Shareholders
- Understanding Recent Voting Rights Acquisition in Business
- Prosafe SE's Fleet Productivity Update: Strong Performance Insights
- Future 500 Forum Aims to Empower Europe's Next Business Leaders
- Future 500 Forum: Elevating Europe's Next Business Leaders
- Exploration of Fishery By-Products and Market Growth Insights
- Innovative Solutions at XCMG's Global Mining Summit Showcased
- AB KN Energies Reports Strong Growth in First Half of 2025
- DeepSeek Enhances V3 Model with Local Chip Technology
- Arthur Hayes' Bold Stance on Federal Reserve Policies Unveiled
- Aker Carbon Capture ASA: Understanding Liquidation Steps
- Aker Carbon Capture ASA Enters Liquidation Process After Meeting
- Skanska's Innovative Health Sciences Facility Construction
- Sampo plc's Strategic Share Buybacks and Their Impact
- Endeavour Mining's Recent Share Buyback Highlights Growth
- Bavarian Nordic's Impressive First Half of 2025 Performance
- Bavarian Nordic's Remarkable H1 2025 Performance Highlights
- Transforming Wellness: Dr. Kiat's New Digital Health Initiative
- NHTSA Investigation on Tesla for Delayed Self-Driving Reports
- Fiserv, Inc. Investors Can Join Potential Class Action
- BTS Group Reports Interim Growth and Leadership Changes
- Stockwik's Impressive Financial Growth in 2025 Quarter Report
- Grigeo Group AB Reports Growth in Consolidated Sales for 2025
- Prosafe SE Reports Q2 Results and Business Outlook for 2025
- BTS Group AB Reports 2025 Mid-Year Financial Highlights
- Stockwik Reports Remarkable Growth in Financial Results
- Prosafe SE Achieves Strong Financial Performance in Q2 2025
- BJ's Wholesale Club: Earnings Predictions and Analyst Insights
- Exploring the Surge in Medical Equipment Maintenance Market
- Understanding the Economic Impact of Trump's Tariffs
- Exploring the Rising Tide of Blue Ammonia Industry Growth
- Nvidia Faces Setbacks as Demand for Local Chips Surges
- Azitra Inc. Experiences Remarkable 59% Rally in After-Hours